Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
56.1M
-
Number of holders
-
84
-
Total 13F shares, excl. options
-
47.9M
-
Shares change
-
-1.36M
-
Total reported value, excl. options
-
$103M
-
Value change
-
-$13.8M
-
Put/Call ratio
-
23.93
-
Number of buys
-
48
-
Number of sells
-
-43
-
Price
-
$2.14
Significant Holders of Black Diamond Therapeutics, Inc. - Common Stock (BDTX) as of Q4 2024
129 filings reported holding BDTX - Black Diamond Therapeutics, Inc. - Common Stock as of Q4 2024.
Black Diamond Therapeutics, Inc. - Common Stock (BDTX) has 84 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 47.9M shares
of 56.1M outstanding shares and own 85.42% of the company stock.
Largest 10 shareholders include T. Rowe Price Investment Management, Inc. (10.5M shares), Bellevue Group AG (8.52M shares), Vestal Point Capital, LP (5.6M shares), NEA Management Company, LLC (4.45M shares), BlackRock, Inc. (3.52M shares), VANGUARD GROUP INC (2.41M shares), TANG CAPITAL MANAGEMENT LLC (2.07M shares), Siren, L.L.C. (1.05M shares), GEODE CAPITAL MANAGEMENT, LLC (959K shares), and RENAISSANCE TECHNOLOGIES LLC (904K shares).
This table shows the top 84 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.